Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13165466 | 0.83 | ALDH1A1 (0.44) | ALDH1A1KMT2ANPSR1PLAUMAPK1 | |
| SCHEMBL17177782 | 0.82 | CHRNB2 (0.38) | ALDH1A1CYP11B2CYP11B1KMT2APIK3CA | |
| SCHEMBL17173641 | 0.82 | ALDH1A1 (0.36) | ALDH1A1CYP11B2CYP11B1KMT2APLAU | |
| SCHEMBL15201125 | 0.81 | GCK (0.44) | ALDH1A1CYP11B2PLAU | |
| SCHEMBL20033736 | 0.79 | ALDH1A1 (0.42) | ALDH1A1KMT2ANPSR1PLAUMAPK1 | |
| SCHEMBL31214124 | 0.79 | ALDH1A1 (0.42) | ALDH1A1KMT2ANPSR1PLAUMAPK1 | |
| SCHEMBL17196427 | 0.77 | L3MBTL1 (0.42) | ALDH1A1KMT2AMEN1NPSR1MAOB | |
| SCHEMBL21419053 | 0.77 | KMT2A (0.46) | ALDH1A1CYP11B2KMT2AMEN1MAOB | |
| SCHEMBL20033674 | 0.76 | ALDH1A1 (0.40) | ALDH1A1NPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL15201780 | 0.76 | GCK (0.44) | ALDH1A1KMT2AMEN1NPSR1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026241-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2011-09-27 | — | — | US | disclosed |
| WO-2010092342-A1 | ORGANOSILICON COMPOUNDS AND THEIR USE AS THE MODULATORS OF THE TRPV1 RECEPTOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-19 | — | — | WO | disclosed |
| US-7582761-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-06-04 | — | — | US | disclosed |
| EP-1551811-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Amgen Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004035549-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV3, TRPV2 | ALDH1A1 2629/4885CYP11B2 2240/4885CYP11B1 2541/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | ALDH1A1 2522/4885CYP11B2 1810/4885CYP11B1 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.